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Abstract 
Aims: Previous reports have demonstrated that alterations or reduced expression 
of Dystroglycan 'JFRPSOH[ Į'JDQGȕ'JVXEXQLWVDUH UHODWHG WRSURJUHVVLRQ
and severity of neoplastic solid tissues. Therefore we determined the expression 
pattern and subcellular distribution of Dg complex in Acute Myeloid Leukemia 
(AML) primary blasts (M1, M2, and M3 phenotypes), as well as HL-60 and Kasumi-
1 leukemia cell lines. Additionally, we evaluated the relative expression of the main 
HQ]\PHV FRQWUROOLQJ Į-Dg glycosylation to ascertain the post-translational 
modifications in the leukemia cell phenotype.   
Main methods: Primary leukemia blasts and leukemia cell lines were processed by 
confocal analysis to determine the subcellular distribution of Į-'J ȕ-Dg, and 
SKRVSKRU\ODWHGȕ-Dg (Y892), to evaluate the expression pattern of the different Dg 
species we performed Western Blot (WB) assays, while the messenger RNA 
P51$ H[SUHVVLRQ RI HQ]\PHV LQYROYHG LQ Į-Dg glycosylation, such as 
POMGnT1, POMT1, POMT2, LARGE, FKTN, and FKRP, were evaluated by 
qualitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). Finally, 
in an attempt to ameliorate the leukemia cell phenotype, we transfected leukemia 
cells with a plasmid expressing the Dg complex.  
Key findings: The Dg complex was altered in leukemia cells, including decreased 
P51$ SURWHLQ DQG Į-'J JO\FRV\ODWHG OHYHOV PLVORFDOL]DWLRQ RI ȕ-Dg, and a 
diminution of mRNA expression of LARGE in patients leukemia blasts and in cell 
lines. Interestingly, the exogenous expression of Dg complex promoted filopodial 
formation, differentiation, and diminished proliferation, attenuating some HL-60 and 
Kasumi cells characteristics. 
Significance: Dg complex integrity and balance are required for a proper 
hematopoietic cell function, in that its disruption might contribute to leukemia 
pathophysiology.  
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1. Introduction 
 
Dystroglycan (Dg) is encoded by the DAG1 gene, generating a polypeptide 
precursor of 895 amino acids, which undergoes post-translational proteolytic 
FOHDYDJH UHVXOWLQJ LQ WZRQRQFRYDOHQWO\DVVRFLDWHGVXEXQLWVĮDQGȕ [1, 2]Į-Dg 
plays important roles in the deposition, organization, and stability of basement 
membranes [3] ZKLOH ȕ-Dg is a transmembrane protein with its cytoplasmic tail 
bound to utrophin or dystrophin, two spectrin-like molecules that interact with a 
number of proteins, including F-actin [4]. 
The physiological role of Dg is to establish communication between cells and their 
microenvironment, making connections with the extracellular matrix proteins and 
cytoskeletal elements. The following three different types of glycan modifications 
H[WHQVLYHO\ GHFRUDWHĮ-Dg: mucin-type O-glycosylation; O-mannosylation, and N-
JO\FRV\ODWLRQ7KHVWDWHRIĮ-Dg glycosylation has shown to be critical for the ability 
of the protein to bind to laminin globular domain-containing proteins of the 
ExtraCellular Matrix (ECM) [5]. Laminins are part of several proteins that comprise 
the ECM and that modulate functions such as cell proliferation, adhesion, 
migration, differentiation, cell polarity, responsiveness to soluble factors, and 
angiogenesis [6, 7]ȕ-Dg also participates in cell signalling through a scaffolding 
role for the ERK/MAPKinase pathway, and by signalling through the 
SKRVSKRU\ODWLRQRIW\URVLQHRIȕ-Dg by Src, regulating the interaction between 
Dg and dystrophin, utrophin and other cytoskeletal binding partners [8, 9]. 
The interaction of Dg with laminin depends on O-linked carbohydrate modifications 
RIWKHĮ-Dg mucin domain that, in turn, depend on a large number of glycosylation 
SDWKZD\HQ]\PHV LQYROYHG LQĮ-Dg modification [10]. Defects of Dg glycosylation 
caused by a loss of function of this protein as an ECM receptor manifest in a wide 
spectrum of muscular and brain abnormalities [11, 12] as well as in cancer cell 
lines [13-15].  
&KDQJHVLQĮ-Dg glycosylation may also play a role in cancer progression [16, 17], 
which may have an important anti-tumorigenic function [14]; in addition, aberrant 
GHJUDGDWLRQRIȕ-Dg through MMP-2 and MMP-9 has been recorded as a relevant 
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event observed in several tumor cell lines and in inflammatory diseases [16, 18].  
In healthy blood cells, Dg has been described as forming part of actin-based 
structures such as filopodia and the lamellipodia of platelets [19] and neutrophils 
[20], contributing to the polarization of the activated forms of these cells. In the HL-
60 leukemia cell line, in addition to a structural role, Dg exhibited an important role 
in modulating the differentiation process of neutrophils, increasing their expression 
level [21], while in Kasumi-1, another acute leukemia cell line, Dg is dispensable 
for macrophage differentiation, but is essential for their activities such as 
phagocytosis and migration, both actin-based functions [22].  
The aim of the present study was to characterize the expression and subcellular 
distribution of Dgs of primary blast cells from patients with Acute Myeloid Leukemia 
(AML), as well as HL-60 and Kasumi-1 cell lines in relation to stem-progenitor cells 
from Healthy Individuals (HI). Additionally, we investigated the glycosylation status 
RI Į-'J DV ZHOO DV WKH H[SUHVVLRQ OHYHOV RI VL[ RI WKH NQRZQ Į-Dg modifying 
proteins in leukemia cells. Our results strongly suggest that the decreased 
H[SUHVVLRQDQGGHJUDGDWLRQRI'JDVZHOO DV WKH UHGXFHGJO\FRV\ODWLRQRIĮ-Dg, 
are in accordance with the immaturity of the cells and contribute to leukemia 
pathogenesis. In support of this, the restoration of Dg expression in leukemia cell 
lines led to the reversion of some of the characteristics associated with the 
disease.  
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2. Materials and Methods 
 
2.1. HL-60 and Kasumi-1 cell culture and differentiation 
HL-60 (ATCC¨ CCL- ZHUHFXOWXUHGLQ,VFRYH¶V 0RGLILHG'XOEHFFR¶V0HGLXP
(IMDM) and Kasumi-1 cells (ATCC¨ CRL- were cultured in RPMI-1640 
medium supplemented with 10% Fetal Bovine Serum (FBS), 400 mM L-glutamine, 
 ȝ0 *HQWDPLFLQ  P0 +(3(6  J/ VRGLXP ELFDUERQDWH  P0 VRGLXP
pyruvate in a humid atmosphere of 5% CO2 at 37¡C. For differentiation into a 
neutrophil phenotype, HL-60 cells (HL-60 D) were differentiated with 1.3% (v/v) 
(DMSO) for 7 days [23], while for differentiation into macrophage-like cells, 
Kasumi-1 cells (Kasumi-1 D) were differentiated with 10±7 M 12-0-
TetradecanoylPhorbol-13-Acetate (TPA) for 7 days [24]. In both cases, cell viability 
was assessed by exclusion of 0.2% Trypan Blue and was routinely >90% before 
and after differentiation.  
 
2.2. Acute Myeloid Leukemia (AML) cells 
Peripheral blood samples were obtained from 43 patients diagnosed with AML. 
Acute leukemia cells have classified in six main types (MI, M2, M3, M4, M5, and 
M6) defined according to (a) the direction of differentiation along one or more cell 
lines, and (b) the degree of maturation of the cells. Thus, M1, M2, and M3 exhibit 
predominantly granulocytic differentiation and differ from each another in terms of 
the extent and nature of granulocytic maturation [25].  
They represent a group of patients with high peripheral blood blast counts who 
were treated either at the Hematology Unit at the Hospital General de Mxico or 
Hospital Jurez de Mxico. In each case, diagnosis was based on morphologic, 
immunophenotypic, and molecular analysis. All samples were obtained with signed 
informed consent by using a protocol approved by the Escuela Nacional de 
Medicina y Homeopata, IPN, Mxico. Patient characteristics are summarized in 
Table 1.  
CD34+ cells were isolated from mononuclear cells from peripheral blood samples 
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using the Dynabeads CD34+ isolation kit cat. 11301D, according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV,QYLWURJHQ/LIH7HFKQRORJLHV&DUOVEDG&$86$ 
Samples from harvested mobilized stem cells were used as stem-progenitor 
controls and they were donated from Banco Central de Sangre del Centro Mdico 
1DFLRQDO³/D5D]D´DIWHUVLJQLQJZULWWHQLQIRUPHGFRQVHQW 
  
2.3. Mobilization regimen and time of harvest 
Thirty-three healthy allogenic stem cell donors underwent mobilization with 
hematopoietic Granulocyte Colony-Stimulating Factor (G-CSF; Neupogen, Amgen, 
0QFKHQ *HUPDQ\ ZLWK  ȝJNJ GLYLGHG LQWR WZR GRVHV DGPLQLVWHUHG
subcutaneously (s.c.). Cells were harvested on the 5th day of mobilization. The 
remainder of the samples used for stem cell quantification was donated for this 
study. 
 
2.4. CD34 positive cell count determination 
CD34 positive cell counts were determined preprocedurally in the autologous 
GRQRU¶VSHULSKHUDOEORRGDQGLQWKHOHXNDSKHUHVLVSURGXFWE\IORZF\WRPHWU\)$&6
Calibur; Becton Dickinson, Heidelberg, Germany). In 48 cases, counting was also 
done in peripheral blood 1 h after the leukapheresis procedure. The flow cytometric 
analysis followed the accepted protocol provided by the International Society of 
Haematology and Graft Engineering. Total Leukocyte Count (TLC) was performed 
in a calibrated automated cell counter (Sysmex XE 2100; Sysmex Corporation, 
Japan) using monoclonal CD34 antibody (clone 8G12; BD Biosciences, San Jose,, 
CA, USA) and CD45 (clone 2D1; BD Biosciences). 
 
2.5. Immunofluorescence staining 
Cells from leukemia samples as well as from cell lines (HL-60 and Kasumi-1) were 
adhered to poly-D-lysine-coated coverslips and after 60 min permeabilized and 
fixed with a mixture of 2% p-formaldehyde, 0.04% NP40 in the cytoskeleton-
stabilizing solution PHEM and triton 0.2%. Captured optical sections [z] were 
quantified using ImageJ (NIH, Bethesda, MD, USA) [21]. Filopodia size and 
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number were detected using FiloDetect software from images taken by 
fluorescence microscopy as described previously [26] 
 
2.6 Western blot analysis 
Leukemia sample cells and cell lines were resuspended and lysed with a 2X lysis 
buffer (0.5% NP-40, 2 mM Na3VO4, PMSF) containing a protease inhibitor cocktail. 
Homogenates were sonicated 3 times for 15 sec. The protein concentrations were 
determined by the BCA method. The protein extract was mixed by loading buffer 
(Tris±+&OVRGLXPGRGHF\OVXOIDWHȕ-mercaptoethanol, glycerol, bromophenol blue) 
and boiled for 5 minutes. Whole cell lysates were separated as described in [21]. 
 
2.7. Plasmids and transfection 
Full-OHQJWK PRXVHG\VWURJO\FDQ FRPSOHPHQWDU\ '1$ F'1$ HQFRGLQJ Į- DQGȕ-
dystroglycans was subcloned into the pcDNA3 vector (Invitrogen Life 
Technologies, Carlsbad, CA, USA) with construct fidelity verified by nucleotide 
sequencing as described previously [27].  
HL-60 or Kasumi-1 cells (2 ! 106P/ZHUHWUDQVIHFWHGZLWKȝJ'1$PL[HGZLWK
ȝJRIS(*)3-N3 to mark the transfected cell population (Clontech, Mountain View, 
&$ 86$ XVLQJ D 1XFOHRIHFWRU ,, HOHFWURSRUDWRU $PD[D DFFRUGLQJ WR WKH
PDQXIDFWXUHU¶VUHFRPPHQGDWLRQ/RQ]D:DONHUVYLOOH,QF:DONHUVYLOOH0'86$
Cells were cultured in the presence of Neomycin at 800 µg/mL to select cells that 
expressed dystroglycans and at 400 µg/mL and to obtain stable cultures.  
 
2.8. Quantitative Real-Time PCR 
Total RNA was extracted from Kasumi-1 cells using Trizol Reagent (Life 
7HFKQRORJLHV :DOWKDP 0$ 86$ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV
One hundred ng of total RNA was subjected to Real-Time PCR performed in 
triplicate using KAPA SYBR FAST One-Step qRT-PCR kit; Kapa Biosystems, 
Wilmington, MA, USA) LQ D ILQDO YROXPH RI  ȝ/ 4XDQWLWDWLYH DVVHVVPHQW RI
mRNA expression was performed by Real-Time-RT-PCR (qRT-PCR) as described 
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in Supplemental Materials and Methods; a primer sequence table is also included 
in Supplemental Materials and Methods. Triplicate Ct values for Dg, POMGnT-2, 
POMT-1, POMT-2, LARGE, Fukutin, FKRP and GlycerAldehyde-3-Phosphate 
DeHydrogenase (GAPDH) were obtained from six different patients with the three 
different leukemia phenotypes.  
 
2.9. Analysis of cell-surface antigens by immunofluorescence flow cytometry 
Cells at 1 ! 105P/ȝ/ZHUHLQFXEDWHGZLWKPRQRFORQDODQWLERG\IRUPLQ
at 4¼C, washed twice with Phosphate-Buffered Saline (PBS) solution, and 
VXVSHQGHG IRUPLQDW & LQȝ/RI$OH[D-conjugated goat anti-rabbit 
IgG (Molecular Probes Kallestad Laboratories, Inc., Austin, TX, USA) as previously 
described [21]. Results were presented as percentages of positive cells for each 
antigen. 
 
2.10. Phagocytosis assays 
Differentiated Kasumi-1 cells were allowed to interact at 37¡C with Phalloidin-
TRITC-labelled Candida glabrata, as described in [21]. 
 
2.11. MTT assay 
Cell proliferation after transfection with the empty vector and Dg+ were measured 
by the (MTT) assay (ATCC¨ 30-1010K). HL-60 and Kasumi-1 cells (1 ! 103/100 
µL) were seeded in 96-well microplates and cultured for 9 days. A viability assay 
using Trypan Blue was assessed each day to ensure that survival was not 
compromised (minimal viability corresponded to 92% at day 9 for HL-60 cells and 
80% for Kasumi-1 cells). After the incubation time, 20 µL of the MTT solution (5 
mg/mL) was added to each well and incubated for another 3 h at 37¡C. The 
formazan crystal formed by the living cells was dissolved with 150 µL of DMSO 
overnight. Then, Optical Density (OD) was measured using the Epoch Microplate 
Spectrophotometer (BioTek, Winooski, VT, USA) at 570 nm. The data were 
processed in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).  
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2.12. Statistical analysis 
Statistical analysis was carried out with GraphPad Prism for Windows ver.5 
software (GraphPad Software) Inc.). Relative protein expression and relative 
mRNA expression were analyzed with an unpaired Student t test. Statistical 
significance was defined as p <0.05.  
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3. Results 
 
3.1. Dystroglycan Distribution in Leukemia Primary Blasts and Cell Lines 
 
To evaluate the subcellular distribution of Dg subunits, double immunofluorescence 
staining and confocal microscopy analysis on blasts of patients with AML (subtypes 
M1, M2, and M3; Table 2S), leukemia cell lines (HL-60 and Kasumi-1) compared to 
stem-progenitor cells from Healthy Individuals (HI) from mobilized cells were 
performed utilizing antibodies raised against Į-'Jȕ-'JDQGȕ'JS<revealed 
with Alexa-Fluor-488 secondary antibody. We analyzed images from five different 
patients corresponding to each subtype (M1, M2, and M3). However, as the 
subcellular distribution did not vary importantly, representative images of M1 
subtype are described and included in Figure 1, while representative images from 
subtypes M2 and M3 appeared in Supplemental Figure 1S. Actin filaments were 
identified with Tetramethyl Rhodamine Iso-ThioCyanate (TRITC)-phalloidin. In the 
cells of HI (Figure 1 A), the Į-Dg subunit displayed a punctate pattern distributed at 
the plasma membrane and scarce distribution in the cytoplasm where it co-
localized with actin filaments and in the nucleus. This distribution was very similar 
to that observed in AML cells irrespective of the type of leukemia (M1, Figure 1B; 
0 DQG 0 6XSSOHPHQWDO )LJXUH 6 ȕ-Dg and its phosphorylated form were 
observed with a homogeneous pattern in the all of the cells, including the nuclei of 
CD34+ cells from individuals with leukemia.  
7KH Į-Dg distribution in HL-60 and Kasumi-1 cells was very similar to that 
GHVFULEHG IRU FHOOV IURP SDWLHQWV ZKLOH ȕ-Dg distribution and its phosphorylated 
form were observed in the cytoplasm, plasma membrane, and nuclei (Figures 1C). 
,QWKHFHOOVRI+,ȕ-DgpY892 was observed exhibiting a patchy pattern restricted to 
the plasma membrane and cytoplasm; this feature is the most relevant and 
consistent finding among the processed samples. Therefore, the important 
difference observed for dystroglycan distribution is related to the differing nuclear 
localization of ȕ-DgpY892 in all leukemia cells compared to healthy CD34+ cells. 
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3.2. Dg Is Downregulated in Leukemia Cells 
 
To characterize the expression pattern of Į-Dg in primary leukemia blasts, we 
processed representative samples (n = 6) in triplicate of each of the three different 
phenotypes classified according to FAB (French-American-British group) as M1, 
M2, and M3 (Table 2S). These samples were analyzed using WB analysis with 
mouse monoclonal antibodies against Į-'J FRUH SURWHLQ & ȕ-Dg (Mandag), 
DQG WKHȕ-'JSKRVSKRU\ODWHG IRUP ȕ-DgpY892). The Į-Dg core protein revealed 
by the presence of a 70-kDa band observed in both the control group of HI as well 
as for AML cells. The use of ȕ-Dg antibody (Mandag) confirmed comparable levels 
RIȕ-Dg proteins among the leukemia samples but lower in relation to controls. A 
similar result was observed when the phosphorylated species of ȕ-Dg was 
analyzed. The relative abundance of the protein was normalized with GAPDH as a 
loading control, demonstrating a statistical significant reduction (p <0.05) with all of 
the Dg species assayed in AML cells as compared to control (Figure 2A). We also 
assessed the Dg pattern expression in leukemia cell lines (HL-60 and Kasumi-1) 
by carrying out WB analysis; a 70-kDa band was detected with 6C1 antibody. A 
low-intensity band of 43 kDa using Mandag antibody was observed in leukemia cell 
line samples compared to HI. This same pattern was observed with a 43-kDa band 
ZKHQȕ-DgpY892 was evaluated (Figure 2B).  
To corroborate the diminished level expression of dystroglycan in AML cells and 
leukemia cell lines observed by WB assays, we analyzed mRNA expression from 
M1, M2, and M3 leukemia primary blasts (n = 6 for each subtype) and leukemia 
cell lines by quantitative Reverse Transcription-PCR (qRT-PCR) (Figures 2C and 
2D, respectively). mRNA expression of dystroglycans was significantly lower for 
AML primary blasts as well as for leukemia cells, respectively, compared to CD34+ 
cells from HI (p <0.05), and this reduction appears to correlate with the immaturity 
of the cells. 
In order to assess the effect of AML1-ETO on Sp1 transcription factor on DAG 
gene promotor regulation [28, 29], we processed, in triplicate, nuclear extracts from 
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leukemia cell lines and HeLa cells for WB assays using Sp1 antibody. The results 
revealed that Sp1 is reduced in leukemia cell lines compared to epithelial cervix 
carcinoma cells (HeLa) (Figure 2E). 
 
 
3.3. Changes in Dystroglycan Post-translational Modification 
 
To characterize the biochemical properties of glycosylated Į-Dg species in primary 
leukemia blasts, we processed representative samples of three different 
phenotypes classified according to FAB as M1, M2 and M3 by WB analysis with 
mouse monoclonal antibodies IIH6C4 mouse monoclonal antibodies. This antibody 
recognizes glycosylated epitopes on Į-Dg, as well as revealing hypoglycosylation 
in the absence of epitopes for the antiERG\ZKHQFRPSDUHGWRWKHWRWDOĮ-Dg core 
protein levels [30]. 
WB with IIH6C4 detected 140-kDa bands in the control group (HI), the reactivity of 
this antibody for the 140 kDa and the lower bands were reduced in leukemia 
SDWLHQWV¶ FHOOV UHODWLYH WR FRQWUROV (arrow). The relative abundance of the protein 
was normalized with GAPDH as loading control showing a statistical significance 
reduction (p <0.05) with all the Dg species assayed in AML cells as compared to 
control (Figure 3A). We also assessed the glycosylation state of Į-Dg within the 
two leukemia cell lines (HL-60 and Kasumi-1) by carrying out WB analysis, which 
was revealed with a band of 140 kDa observed using IIH6C4. A statistically 
significant reduction in intensity of the 140-kDa band (p <0.05) was observed in 
samples from the two leukemia cell lines (Figure 3B). Other bands of Į-Dg protein 
with lower molecular weight can be visualized with long exposure times. 
According to our WB results in cell lines and leukemia cells from patients, we 
inferred that there might be Dg glycosylation defects in Į-subunit, as has been 
observed in cancer cell lines from solid tissue [31]. Thus, we assessed the 
expression level of mRNA of some of the main enzymes that modulate Dg 
glycosylation, including POMGnT1, POMT1, POMT2, LARGE, FKTN, and FKRP, 
[11, 32] by carrying out qRT-PCR analysis of these six enzymes. Figure 3C shows 
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a heterogeneous pattern expression of the six glycosyltransferases for AML 
leukemia cells; POMGNT-1, POMT-1, POMT-2, and Fukutin are expressed to a 
greater degree in leukemia samples than in HI, except for LARGE and FKRP. 
While the qRT-PCR assays of the six glycosyltransferases (POMGnT1, POMT1, 
POMT2, LARGE, FKTN, and FKRP) in AML cell lines (Figure 3D) demonstrates 
the relative reduction in the expression of the six glycosyltransferases in both HL-
60 and Kasumi-1 cell lines. In HL-60 cells, nearly all the enzymes assayed are 
expressed with lower values than those observed for Kasumi-1 cells- LARGE 
mRNA levels are similar for both cell lines, while Fukutin is nearly absent for 
Kasumi-1 cells.  
 
 
3.4. Restoration of Dg Levels in Leukemia Cell Lines 
 
To investigate whether restoration of Dg was sufficient to reduce proliferation and 
to improve differentiation and the functional properties of leukemia cells, we 
modified HL-60 and Kasumi-1 cells to stably express Dg (Dg+). HL-60 cells 
showed good expression of the transgene at the protein level, but to a lesser 
extent in Kasumi-1 cells observed by a 70-N'DEDQGFRUUHVSRQGLQJ WRȕ-Dg and 
GFP; however, qRT-PCR results were consistent for both cell lines (Supplemental 
Figure 1). 
The proliferation process was directly evaluated by MTT assays from HL-60 and 
Kasumi-1 synchronized cultures; our results revealed that cells expressing (Dg+) 
diminished their proliferation compared to cells that were transfected with the 
Empty Vector (EV), suggesting that Dg modulates the proliferation process for both 
cell lines (Figure 4A). The differentiation process triggered by DMSO typical and 
functional characteristics will be present, such as phagocytic capability. Therefore, 
after 7 days of treatment with DMSO, the differentiated cells might phagocyte C. 
glabrata, in contrast to non-differentiated cells; however, to our surprise, HL-60 
non-differentiated cells that were overexpressing Dg (Dg+ ND) acquired the 
phagocytic capability at the same level as control differentiated cells (HL-60 D) 
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(Figure 4B). This characteristic reached nearly 70% of the differentiated population 
overexpressing Dg (Dg+ D). On the other hand, Kasumi-1 cells did not show a 
significant difference between the phagocytic characteristic between differentiated 
(Dg+ D) and non-differentiated (Dg+ ND) cells that were overexpressing Dg; a 
difference was found between the differentiated cells overexpressing Dg (Dg+ D) 
and the Empty Vector (EV D) (Figure 4C).  
Finally, to corroborate whether the phagocytic characteristic was in accordance 
with the differentiation process, we evaluated by flow cytometer the presence of 
CD11b, which is a typical differentiation marker for neutrophil lineage. Our results 
revealed that CD11b expression was present in cells stably transfected with EV, 
Dg+, or non-transfected cells treated with DMSO and again untreated Dg 
overexpressing cells (Figure 4E). Kasumi-1 cells treated with PMA were 
differentiated to macrophage lineage, which was corroborated by the detection of 
CD68 at the surface of the cells. This marker was present at the surface of 
differentiated cells whether or not they overexpressed Dg (Figure 4F).   
 
 
3.5. Dystroglycan Promotes Filopodial Formation in Leukemia Cell Lines 
 
Previously, we reported that dystroglycan small interfering RNA (siRNA) decreased 
filopodia number and length in HL-60 and Kasumi-1 cells, as well as the functions 
related with actin-based structures [21, 22]. Therefore, F-actin from HL-60 and 
Kasumi-1 cells overexpressing Dg and controls were labelled with phalloidin to 
evaluate relative fluorescence units and number and length of filopodia during the 
differentiation process. 
Panel A depicts the morphology of HL-60 cells through the differentiation process 
triggered by DMSO; filopodia were more evident on days 5 and 8 of treatment in 
Dg+ HL-60 cells. Panel B illustrates the morphology displayed by Dg+ and EV of 
Kasumi-1 cells during PMA treatment. The insets present filopodia detected by the 
software (observed in green); the number and length of these structures, as well as 
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F-actin intensity, were quantified along the differentiation process for both cell 
types.   
Along the differentiation process (7 days), HL-60 cells did not exhibit an important 
difference related with F-actin content or filopodia length, however, we observed an 
increase in the number of filopodia in Dg+ cells, which is more evident at the end of 
the differentiation process (Figure 5A).  
For Kasumi-1 cells, relative F-actin content is apparently heterogeneous and does 
not increase as the cell differentiates. The length of filopodia showed a short 
increase as the cell is differentiated; however, there is no difference between Dg+ 
cells and the controls (EV). On the other hand, the number of filopodia is increased 
in accordance with the advance of the differentiation process, and the values are 
statistically significant for days 5 and 8 of differentiation (Figure 5B). 
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4. Discussion 
 
In the present study, we show, to our knowledge for the first time, the expression 
pattern and subcellular distribution of Dg in primary blasts from patients with acute 
leukemia. In this pathology, protein levels corresponding to the Dg core protein, the 
gO\FRV\ODWHG VSHFLHV RI Į-'J DV ZHOO DV IRU ȕ-Dg and its phosphorylated form 
demonstrated reduced expression. This diminution does not correlate universally 
with clinical severity, as reported for other systems [33], in contrast to the 
transcriptional level detected with qRT-PCR assays.  
The AML1-ETO fusion protein indicates Acute Myeloid Leukemia (AML) with 
t(8;21)(q22;q22), present in10±15% of all AML cases [34], although AML is 
induced unless secondary mutations take place [35]. Specificity protein 1 
transcription factor (Sp1) regulates the Dag1 gene [29] and interacts with AML1-
ETO, leading to Sp1 transactivity inhibition [28]. We confirmed the diminished 
expression of Sp1 in leukemia cell lines by WB assay and this might explain low 
level of Dg mRNA low levels. 
The presence of Dg in the nucleus has been recently described, forming part of the 
nucleoskeleton, as well as modulating the transcriptionally active regions [36]. The 
presence of ȕ-DgpY892 in the nucleus of leukemia cells might be indicative of 
active ubiquitination, which in turn might exacerbate dysregulation in proliferation 
and differentiation processes, as has been proposed for prostate [37].  
Because we did not use a Furin inhibitor in the present study, a diminished relative 
molecular weight of Į-Dg (140 kDa) was evident compared to the data reported in 
our previous studies for HL-60 and Kasumi-1 cells (160 kDa) [21, 22]. Thus, we 
K\SRWKHVL]H WKDW SURWHRO\VLV RI WKH ȕ-Dg ectodomain [38] RU RI Į-'J¶V 1-terminal 
portion [39-41] SURGXFHG E\ 0DWUL[ 0HWDOOR3URWHLQDVHV 003 )XULQ DQG Ȗ-
secretase [42], respectively, may contribute to the pathophysiology of the AML, as 
these have been implicated in cancer progression in other systems [43, 44]. 
5HFHQWO\LWZDVHVWDEOLVKHGWKDWK\SRJO\FRV\ODWLRQVHYHUHO\DOWHUVĮ-'J¶VFDSDELOLW\
to bind to ECM partners, facilitating its degradation by MMP-2 or by other enzymes 
not identified to date [45]; additionally, in some patients affected by 
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dystroglycanopathy, an important reduction of the Dg core protein was identified 
[46]. These events are in accordance with our results, in that we simultaneously 
observed a significant reduction in glycosylated Į-Dg forms, as well as a reduction 
of Dg core protein. 2Q WKH RWKHU KDQG WKH FOHDYDJH RI ȕ-Dg due to 
MetalloProteinases (MP) generates a 31-kDa fragment that is directed to the 
proteasome for degradation [39]; however, this form was not evident for the 
samples processed in the present study.  
A smaller Į-Dg form was also observed (110 kDa) regardless of the source of the 
sample (patient or cell line); this form should not be detected by the carbohydrate-
dependent IIH6 antibody, suggesting alteration in Į-Dg glycosylation and loss of 
receptor function, as has been described for skeletal muscle in patients with 
dystroglycanopathy [30]. In support of these findings, we performed the 
quantification of six of the enzymes responsible for O-linked carbohydrate 
modifications of the Į-Dg mucin domain that, in turn, modulate laminin anchoring, 
because similar defects have been observed in cancer cell lines [13, 14, 31, 39]. 
Results derived from AML blast cells as well as from leukemia cell lines converged 
in diminished LARGE expression. In some cancers, methylation changes at the 
promoter of this glycosylation enzyme leads to the loss of its protein expression 
[15]. The presence of non functionally-JO\FRV\ODWHG Į-Dg might contribute to the 
activity of MEK and AKT, and is responsible for poor clinical outcomes, as 
previously suggested [13].  
Dg glycosylation regulated via N- or O- glycosylation sites [32] is a requirement for 
cells to bind to a wide range of ECM components to control cell survival, 
proliferation, and differentiation via cell surface receptors [47]. We have 
demonstrated that Dg glycosylation is highly regulated during the differentiation 
process of blood tissue cells, affecting their implicit functions [21, 22]. In the 
present study, we show that Dg glycosylation is differentially regulated and a failure 
in the glycosylation of laminin exists as a biochemical characteristic of acute 
leukemia cells, although we did not explore LARGE overexpression, which might 
SDUWLDOO\UHVFXHIXQFWLRQVUHODWHGWRĮ-Dg glycosylation.  
 AML is a molecular and clinical heterogeneous disease [48] and, although there is 
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a direct correlation between AML cases with mutations (8:21) and the quantity of 
Dgs, the most important factor in the presentation of the disease might be 
attributed to the numerous defects found in terms of the quality of the Dgs system. 
Therefore, restoration of dystroglycans by stably transfecting leukemia cell lines 
(HL-60 and Kasumi-1 cells), with a plasmid expressing Dg nearly recovering the 
healthy phenotype as the proliferation process was reduced; the differentiation 
process, as well as actin-based functions (phagocytosis), were increased, 
demonstrating the importance of Dg structural and signalling roles in acute 
leukemia pathophysiology.  
 
 
5. Conclusion 
 
Our results strongly suggest that the balance and integrity between the 
dystroglycan alpha and beta subunits are indispensable and responsible for the 
cell differentiation and proliferation in acute leukemia cells. Further studies will be 
needed to determine whether the Dg could be useful as a potential biomarker not 
only to diagnose leukemia, but also to determine the prognosis of the disease. 
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Figure Legends 
 
Figure 1. Subcellular distribution of dystroglycans in acute leukemia cells.  
CD34+ stem-progenitor cells from Healthy Individuals (HI) Panel A, primary blast 
cells from M1 in patients with Acute Myeloid Leukemia (AML-1) Panel B, and HL-
60, and Kasumi-1 Panel C, were placed on glass coverslips were processed for 
double immunofluorescence microscopy using anti-dystroglycan antibodies 
(green), phalloidin (red) to visualize the F-actin network and DAPI (blue) for nuclei 
were DQDO\]HGE\FRQIRFDOPLFURVFRS\%DU ȝP.  
 
Figure 2. Pattern of expression of dystroglycans in acute leukemia cells.  
Panel A. Total lysates of primary blast cells from M1, M2, and M3 in patients with 
Acute Myeloid Leukemia (AML-1, AML-M2, AML-3) were analyzed by Western Blot 
:%XWLOL]LQJDQWLERGLHVDJDLQVWWKHĮ-Dg core protein (6C-ȕ-Dg (Mandag), and 
ȕ'JS< 4XDQWLWDWLYH DQDO\VLV XVLQJ *$3'+ DV ORDGLQJ FRQWURO LV VKRZQ
Values depicted are mean ± Standard Error of the Mean (SEM) from three 
independent experiments (n = 3), respectively. *P <0.005; **P <0.003. Panel B. 
Total lysates of CD34+ stem-progenitor cells from Healthy Individuals (HI), HL-60, 
and Kasumi-1 cells were analyzed as mentioned previously. Panel C. Messenger 
RNA (mRNA) expression of dystroglycan was examined by quantitative Reverse 
Transcription-PCR (qRT-PCR) in primary blast cells from M1, M2, and M3 in 
patients with Acute Myeloid Leukemia (AML-1, AML-M2, AML-3) compared to 
CD34+ stem-progenitor cells from Healthy Individuals (HI). Values shown are mean 
± Standard Error of the mean (SEM) from six different patients performed in 
triplicate, respectively. Panel D. Messenger RNA (mRNA) expression of 
dystroglycan was examined by quantitative Reverse Transcription-PCR (qRT-PCR) 
in primary blast cells from HL-60 and Kasumi-1 cells compared to CD34+ stem-
progenitor cells from Healthy Individuals (HI). Values depicted are mean ± 
Standard error of the Mean (SEM) from three independent experiments (n = 3), 
respectively. *P <0.05; **P <0.03. Panel E. Total extracts from HeLa, and Western 
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Blot (WB) utilizing an antibody against Sp1 and actin as a loading control analyzed 
nuclear extracts from HL-60 and Kasumi-1 cells. 
 
Figure 3.  'HUHJXODWLRQLQĮ-Dg glycosylation in leukemia cells. 
Panel A. Total lysates of primary blast cells from M1, M2, and M3 in patients with 
Acute Myeloid Leukemia (AML-1, AML-M2, AML-3) were analyzed by Western Blot 
(WB) utilizing an antibody against the central mucin-OLNH UHJLRQRIĮ-Dg (IIH6C4). 
Quantitative analysis using GAPDH as loading control is shown. Panel B. Total 
lysates of CD34+ stem-progenitor cells from Healthy Individuals (HI), HL-60, and 
Kasumi-1 cells were analyzed as previously mentioned. Values shown are mean ± 
Standard Error of the Mean (SEM) from three independent experiments (n = 3), 
respectively. *P <0.005; **P <0.003. Panel C. Messenger RNA (mRNA) expression 
of dystroglycan was examined by quantitative Reverse Transcription-PCR (qRT-
PCR) in primary blast cells from M1, M2, and M3 in patients with Acute Myeloid 
Leukemia (AML-M1, AML-M2, AML-M3) compared to CD34+ stem-progenitor cells 
from Healthy Individuals (HI). Values depicted are mean ± Standard Error of the 
Mean (SEM) from six different patients performed in triplicate, respectively. Panel 
D. Messenger RNA (mRNA) expression of the main putative glycosyltransferases 
(POMGnT1, POMT1, POMT2 LARGE, FKRP, and Fukutin) in HL-60 and Kasumi-1 
cells compared to CD34+ stem-progenitor cells from HI was analyzed as described 
previously. Values shown are mean ± SEM from three independent experiments (n 
= 3), respectively. *P <0.05.  
 
Figure 4. Dystroglycan re-expression contributed to correct leukemic phenotype. 
HL-60 cells, Panel A; and Kasumi-1 cells Panel B; transfected with Empty Vector 
(EV) and Dg overexpressing vector (Dg+) were processed for MTT assay for 9 
days at different intervals. Cells overexpressing Dg+ diminished their proliferation 
rates. HL-60 and Kasumi-1 cells transfected with EV and Dg overexpressing vector 
(Dg+) were evaluated for their phagocytic ability by internalization of Candida 
glabrata labelled with phalloidin±TRITC Panel C and panel D respectively. This 
function was more evident for Dg+ cells without regarding the cell line compared to 
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controls. Error bars show ± Standard Error of the Mean (SEM) based on a total of 
three experiments. *P <0.05; **P <0.03.  
HL-60 cells, Panel E and Kasumi-1 cells, Panel F transfected with Empty Vector 
(EV) and Dg overexpressing vector (Dg+) were processed by flow cytometer using 
antibodies against differentiation markers CD11b and CD68 for neutrophils and 
macrophages respectively. The differentiation process was present in Dg+ cells, 
even in non-treated cells. Error bars show ± SEM, based on a total of three 
experiments. *P <0.05. 
 
Figure 5. Dystroglycan overexpression promotes filopodia formation in acute 
leukemic cells. Panel A. HL-60, or Panel B. Kasumi-1 cells, transfected with Empty 
Vector (EV) and Dg overexpressing vector (Dg+) were analyzed by confocal 
microscopy to evaluate morphological changes in response to the increase of 
G\VWURJO\FDQGXULQJWKHGLIIHUHQWLDWLRQSURFHVVGD\V%DU ȝP 
Number and length of filopodia was quantified by FiloDetect software in HL-60 and 
Kasumi-1 cells transfected with Dg (Dg+). Values shown are mean ± Standard 
Error of the Mean (SEM) from three independent experiments each measuring 20 
cells, compared to Empty Vector (EV) controls. ***P <0.001.  
 
 
Supplemental Figure 1 
Subcellular distribution of dystroglycans in acute leukemia cells.  
Panel A. Primary blast cells from M2, and M3 in patients with Acute Myeloid 
Leukemia (AML-M2, AML-3) placed on glass coverslips were processed for double 
immunofluorescence microscopy using anti-dystroglycan antibodies (green), 
phalloidin (red) to visualize the F-actin network and DAPI (blue) for nuclei were 
DQDO\]HGE\FRQIRFDOPLFURVFRS\%DU ȝP 
 
 
Supplemental Figure 2 
HL-60 and Kasumi-1 cells were transfected with vectors expressing Dg (Dg+) or 
 28 
with Empty Vector (EV). Total HL-60 and Kasumi-1 cell extracts were processed 
IRU:HVWHUQ%ORW:%XWLOL]LQJDQDQWLERG\DJDLQVWȕ-dystroglycan; corresponding 
bands were observed at 42 kDa and 70 kDa. Densitometry analysis demonstrated 
ȕ-Dg expressed in cells transfected with a Dg+ vector as compared with cells 
transfected with a control EV. Values shown are mean ± Standard Error of the 
Mean (SEM) from three independent experiments (n = 3), respectively. *P <0.05; 
**P <0.03. 
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